2+ day, 2+ hour ago  (82+ words) biocentury. com Trump administration considering restrictions on China deals China hawks are calling for outbound investment bans to be extended to biotech China hawks in Congress are pressing the Trump administration to invoke national security powers to narrow Chinese life…...

3+ day, 7+ hour ago  (81+ words) Retatrutide data strengthen Lilly's hand in high-BMI obesity biocentury. com Retatrutide data strengthen Lilly's hand in high-BMI obesity Phase III data put weight loss above Cagri Sema's benchmark, with tolerability that may be good enough to preserve a commercial edge…...

4+ day, 6+ hour ago  (92+ words) biocentury. com Poplar: Expanding food allergy treatment with deeper Ig E depletion By dismantling both Ig E signaling and production, start-up aims to create options for patients not reached by Xolair Boston-based Poplar is betting that deeper Ig E reduction…...

4+ day, 2+ hour ago  (90+ words) biocentury. com Hengrui's deal economics: pharma, biotech and New Co breakdown How Hengrui's out-licensing deals stack up across partner types, and why last week's BMS partnership was an outlier Hengrui's broad pipeline has made it a leader in out-licensing innovative…...

2+ week, 5+ day ago  (99+ words) Rev Med maps its next RAS frontier'Bio Century Rev Med maps its next RAS frontier Poised to overhaul PDAC care, Rev Med's longer-term vision spans catalytic inhibition, immune modulation and disease interception With clinical data cementing the value of its…...

2+ week, 5+ day ago  (80+ words) Bio Century At least five PDUFA dates on FDA's May docket One new product via 505(b)(2), plus four label expansions Only five PDUFA dates have been disclosed in May, with the month's lone new product a 505(b)(2) NDA for a new formulation…...

3+ week, 2+ day ago  (103+ words) biocentury. com Proposed ban on China clinical trial data reflects deep concerns in Washington Though unlikely to be adopted, the measure signals strong congressional interest in responding to competition from China Congress took a first step Thursday toward a process…...

3+ week, 6+ day ago  (191+ words) Bio Century New targets at AACR, biopharma deals, Kurma fund " a Bio Century podcast Target discovery, pan-RAS ADCs at the American Association for Cancer Research More than 175 new oncology targets surfaced at this year's American Association for Cancer Research annual…...

3+ week, 6+ day ago  (67+ words) Bio Century Lilly's deal spree continues with Ajax takeout: Deals Report Plus: Sun buying Organon; Be One in trispecifics deal with Huahui; and more Continuing a streak that had already delivered five substantial M&A deals in 2026, Lilly said early…...

1+ mon, 3+ hour ago  (62+ words) Bio Century Nektar parlays alopecia readout into $374 M follow-on: Public Equity Report Plus: Anaptys Bio's autoimmune spinout First Tracks Bio arrives on NASDAQ; and more This week's biggest follow-on went to Nektar, which raised $374 million after new Phase II data…...